<DOC>
	<DOCNO>NCT02228304</DOCNO>
	<brief_summary>Prospective , multi-center 2-stage study . Stage 1 ( Phase I ) open-label patient treat NT-503-3 ECT implant . Stage 1 ( Phase I ) patient undergo explantation year 2 . Those , opinion investigator , still candidate continue anti-VEGF therapy re-implanted new NT-503-3 investigational product follow additional 12 week study exit . Stage 2 ( Phase II ) separate , randomize , mask phase eligible patient randomize NT-503-3 group control group . Clinical Hypotheses : - NT-503-3 ECT comparable EyleaÂ® inject intravitreally every 8 week prevention vision loss due recurrent CNV secondary AMD - NT-503-3 ECT acceptable safety profile</brief_summary>
	<brief_title>Study Intravitreal Implantation NT-503-3 Encapsulated Cell Technology ( ECT ) Treatment Recurrent Choroidal Neovascularization ( CNV ) Secondary Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<criteria>Key Diagnosis Active ( recurrent persistent ) subfoveal CNV lesion secondary AMD study eye Prior Intravitreal AntiVEGF injection Key Significant subretinal hemorrhage Significant Scar and/or , fibrosis Suspected polypoidal choroidopathy , pigment epithelial tear rip Inadequate response antiVEGF therapy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Wet AMD</keyword>
	<keyword>Wet Age Related Macular Degeneration</keyword>
	<keyword>Recurrent CNV Secondary AMD</keyword>
	<keyword>Active subfoveal CNV</keyword>
</DOC>